Intelligence · Clinical Pipeline
Phase III Pipeline Programs
Late-stage pivotal and registrational clinical programs nearing regulatory submission.
- Programs
- 5,427
Quick answer
NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Top sponsors
- Takeda 393 programs
- United Therapeutics Europe 199 programs
- Anaxis Pharma 198 programs
- Chinese Academy of 189 programs
- Teva Pharma 148 programs
- Novartis India 145 programs
- BRIGHT MINDS BIOSCIENCES 139 programs
- PARItec 139 programs
- HOFFMANN-LA ROCHE 134 programs
- Regeneron UK 129 programs
- AstraZeneca 120 programs
- First People's Hospital 117 programs
-
PEG-Interferon a-2b + Ribavirin
Universal Integrated
Chronic Hepatitis C Infection in HIV-Infected Persons
1 trial -
PEG-interferon-Alfa-2A
Hospital Authority, Hong Kong
Chronic Hepatitis B
1 trial -
PEGASPARGASE
Pari Pharma GmbH
This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL
1 trial -
PEGCETACOPLAN (APL-2)
Apellis Europe B.V.
Geographic Atrophy Secondary to Age-related Macular Degeneration
1 trial -
PEGFILGRASTIM , PACLITAXEL , DOXORUBICIN , Rinatabart Sesutecan, GEMCITABINE , TOPOTECAN
Genmab A/S
Platinum-resistant Ovarian Cancer
1 trial -
PEGylated Recombinant Factor VIII
Takeda
Hemophilia A
2 trials -
PEGylated Recombinant factor VIII (rFVIII)
Takeda
Hemophilia A
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Squamous cell carcinoma of head and neck
1 trial -
PEMBROLIZUMAB
Ningbo Cancer Hospital
Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.
1 trial -
PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE
Lacuna Pharma Pty Ltd
Triple Negative Breast Cancer
1 trial -
PEMBROLIZUMAB , BNT113
BioNTech SE
Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer
1 trial -
PEMBROLIZUMAB , IMFINZI 50 mg/mL concentrate for solution for infusion., JZP598, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabin Hikma 38 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Jazz Pharmaceuticals Ireland Limited
BTC - Biliary Tract Cancer
1 trial -
PEMBROLIZUMAB , Matching placebo, EIK1001 solution for injection 1.0 mg/mL free base equivalent
Eikon Therapeutics
Advanced Melanoma
1 trial -
PEMBROLIZUMAB , Placebo to match ly, ENFORTUMAB VEDOTIN
Eli Lilly Co.
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
1 trial -
PEMBROLIZUMAB, IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN, INFLIXIMAB, PACLITAXEL, MYCOPHENOLATE MOFETIL, GEMCITABINE, Datopotamab deruxtecan, PACLITAXEL ALBUMIN-BOUND
AstraZeneca AB
Triple-negative Breast Cancer
1 trial -
PEMBROLIZUMAB, PEMETREXED DISODIUM, CISPLATIN, PEMETREXED DISODIUM, Relatlimab + Nivolumab Fixed Dose Combination (FDC), CARBOPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
1 trial -
PEMETREXED , GEMCITABINE , PACLITAXEL , CISPLATIN , CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion.
Partner Therapeutics Limited
Stage IIB-IIIB (N2) resectable non small cell lung cancer
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN , PACLITAXEL , pembrolizumab, CISPLATIN
Merck Sharp and Dohme
Metastatic (stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
1 trial -
PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN
Pari Pharma GmbH
Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)
1 trial -
PEMETREXED, PALONOSETRON, Adagrasib, PEMBROLIZUMAB, CARBOPLATIN, tablets, CISPLATIN
Bristol-Myers Squibb Australia Pty Ltd
Locally Advanced or Metastatic Non-small Cell Lung Cancer
1 trial -
PEMETREXED, PEMBROLIZUMAB, CISPLATIN, PACLITAXEL, PACLITAXEL ALBUMIN-BOUND, CARBOPLATIN
Ningbo Cancer Hospital
Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line
1 trial -
PEMETREXED, VINORELBINE, Rilvegostomig, MYCOPHENOLATE MOFETIL, ETOPOSIDE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, Datopotamab deruxtecan
AstraZeneca AB
Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-positive result or high-risk pathological feature
1 trial -
PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE
Pari Pharma GmbH
Acute Myocardial Infarction
1 trial -
PF-02341066
Pfizer
Carcinoma, Non-Small-Cell Lung
2 trials -
PF-05280014
Pfizer
Metastatic Breast Cancer
1 trial -
PF-05280586
Pfizer
Follicular Lymphoma
1 trial -
PF-06438179
Pfizer
Rheumatoid Arthritis
1 trial -
PF-06651600 Induction Dose
Pfizer
Alopecia Areata
1 trial -
PF-06801591
Pfizer
Non-muscle Invasive Bladder Cancer
1 trial -
PF-06821497, Tablet to match Placebo for PF-06821497 250mg, PF-06821497, ENZALUTAMIDE, Tablet to match Placebo for PF-06821497 125mg
Pfizer Australia Pty Ltd
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
1 trial -
PF-07275315 dose 1
Pfizer
Moderate to Severe Chronic Obstructive Pulmonary Disease
1 trial -
PF-07321332
Pfizer
COVID-19
2 trials -
PF614 capsule
Ensysce Biosciences
Postoperative Pain, Acute
1 trial -
PG-011 nasal spray 0.6%(twice daily)
Prime Medicine
Seasonal Allergic Rhinitis
1 trial -
PG-011Gel
Prime Medicine
Atopic Dermatitis
1 trial -
PGET
Atrium Therapeutics
Osteoarthritis
1 trial -
PH94B
Vistagen Therapeutics
Social Anxiety Disorder
1 trial -
PH94B Nasal Spray
Vistagen Therapeutics
Social Anxiety Disorder
2 trials -
PHENOXYMETHYLPENICILLIN, PHENOXYMETHYLPENICILLIN
Tour Hekla
Recurrent Erysipelas in lower limbs
1 trial -
PIMECROLIMUS , Amlitelimab, Matched placebo for test, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PIMECROLIMUS , Amlitelimab, Placebo, Amlitelimab, -, TACROLIMUS
Sanofi-aventis Healthcare Pty Ltd
Dermatitis atopic
1 trial -
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion
Pari Pharma GmbH
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection
1 trial -
PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam
Pari Pharma GmbH
Excision-autograft surgery in burn patient
1 trial -
PIRTOBRUTINIB, IBRUTINIB, PIRTOBRUTINIB, IBRUTINIB
Wuhan Createrna Science and Technology Co., Ltd
Mantle cell lymphoma
1 trial -
PIRTOBRUTINIB, IDELALISIB, RITUXIMAB, BENDAMUSTINE HYDROCHLORIDE, PIRTOBRUTINIB, IDELALISIB
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PIRTOBRUTINIB, RITUXIMAB, PIRTOBRUTINIB, BENDAMUSTINE
Wuhan Createrna Science and Technology Co., Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
PL1 - Lyophilisate and solvent for solution for injection, sotatercept
Lacuna Pharma Pty Ltd
Pulmonary Arterial Hypertension (PAH)
1 trial -
PL1 - Placebo to match losmapimod tablets are tablets for oral administration and visually match the active losmapimod tablets, 15 mg., Losmapimod
Fulcrum Therapeutics
Facioscapulohumeral Muscular Dystrophy (FSHD)
1 trial
Frequently asked questions
How many Phase III pipeline programs are in the directory?
5,427 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources · All pipeline programs